fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Kidney Disease Focused Precision Medicine Firm Chinook Therapeutics Presents 6 Posters At ISN World Congress of Nephrology

By John F. Heerdink, Jr.
Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.


Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced on Thursday, April 15th six poster presentations at the ISN World Congress of Nephrology 2021 (WCN ’21).

 

Eric Dobmeier PRESIDENT AND CHIEF EXECUTIVE OFFICER

“The depth and breadth of our presence at this year’s WCN ’21 is a testament to Chinook’s role as a leading kidney disease company. Our data demonstrating BION-1301’s ability to significantly reduce Gd-IgA1 levels in healthy volunteers, as well as the favorable pharmacodynamics of subcutaneous administration of BION-1301, position the program well to move forward in demonstrating its disease-modifying potential for IgA nephropathy patients. In addition, our preclinical poster presentations on atrasentan provide broader insights into its anti-fibrotic and anti-inflammatory properties that are additive and complementary to its proteinuria-lowering mechanism of action.” stated Eric Dobmeier, president and chief executive officer of Chinook.



Here are Chinook’s highlighted posters:

  • Poster presentation on BION-1301 including Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and 2 of the ongoing phase 1b study of BION-1301 and data from the phase 1 IV to SC bioavailability study in healthy volunteers
     
  • Poster presentation on atrasentan’s effect to rapidly reduce albuminuria and downregulate intra-renal transcriptional proliferative, inflammatory and fibrotic signaling in the gddY mouse IgAN model
     
  • Poster presentation on atrasentan’s effect to attenuate human renal mesangial cell activation induced by endothelin-1 or IgAN patient immune-derived immune complexes in a translational model system
     
  • Two informational poster presentations on the phase 3 ALIGN trial design for atrasentan in IgA nephropathy (IgAN) and the phase 2 AFFINITY trial design for atrasentan in proteinuric glomerular diseases
     
  • Encore poster presentation on CHK-336, a first-in-class oral small molecule lactate dehydrogenase A (LDHA) inhibitor with the potential to treat all subtypes of primary hyperoxaluria (PH) and other disorders arising from excess oxalate



Chinook Therapeutics (NASDAQ: KDNY) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. 

Discover more about Chinook Therapeutics at the Vista’s VP Watchlist page by clicking here. 



On Thursday, April 15th CEO Eric Dobmeier & CBO Tom Frohlich of Chinook Therapeutics, Inc. (NASDAQ: KDNY), delivered  a presentation titled  “Revolutionizing The Treatment of Kidney Disease.” If you missed the event, please consider viewing the event video now at the Tribe Pubic YouTube Channel by clicking here!


(Read Original Story: CHINOOK THERAPEUTICS PRESENTS DATA DURING THE ISN WORLD CONGRESS OF NEPHROLOGY 2021 in Chinook Therapeutics (NASDAQ: KDNY))


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us